Androgen Deprivation Therapy Market Segmented By drug class that is Luteinizing Hormone-Releasing Hormone (LHRH) agonists, LHRH antagonists, Antiandrogens with route of administration such as Injectable, Oral
Industry: Healthcare
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Report Type: Ongoing
Report ID: PMRREP31996
Androgen deprivation therapy is a hormone therapy of prostate cancer in males, by depriving the excess amount of androgen. Androgen is a sex hormone produced in the testes and adrenalin gland in the form of testosterone and dihydrotestosterone.
According to the World Health Organization (WHO), prostate cancer is the fourth leading cancer, with 1.3 million global cases. Androgen deprivation therapy comprises the deprivation androgen to curb its detrimental effects such as promoting the cancer cell growth in the early stages and modulate androgen functions.
Androgen deprivation therapy is also coupled with external beam radiotherapy to treat intermediate and high-risk prostate cancer. The global androgen deprivation therapy market is poised to grow lucratively with the rising cases of prostate cancers, also the advancing healthcare and research to fuel the market growth further.
Coronavirus pandemic has also shaped the global androgen deprivation therapy market. It has been found in a study that patients of prostate cancer who received the androgen deprivation therapy were at lower risk of coronavirus. Therefore, these findings indicate that the androgen deprivation therapy market has propelled in the coronavirus crisis.
The growth of the global androgen deprivation therapy market is driven by the rising cases and deaths by prostate cancer, innovative technologies, advancing healthcare expenditure and facilities, increasing global awareness and demand for better treatment. The R&D bodies are actively dwelling to develop novel androgen deprivation therapy for cancer.
The approval of new drugs have also propelled the androgen deprivation therapy market growth. However, the market growth is constrained by the resistance developed during the treatments, side effects such as hot flashes, erectile dysfunction, low bone density, insulin resistance etc.
Androgen deprivation therapy is ineffective for hormone-refractory prostate cancer. The high expenses and poor reimbursement of treatment expenses hinder the market growth. Although, the overall global androgen deprivation therapy market is anticipated to grow further due to the increasing cases of prostate cancer, improving R&D and healthcare facilities.
| By drug class |
|
| By route of administration |
|
| By end-users |
|
The global androgen deprivation therapy market is expected to grow lucratively with the rising cases of prostate cancer, advancing R&D and healthcare. By drug type, the luteinizing hormone-releasing hormone (LHRH) rules the segment due to its massive application into prostate cancer therapy, without causing short term boost of testosterone production during the treatment.
By route of administration, injectable dominates the segment due to their high efficacy and bioavailability. By end-user, the hospitals rule the segment with its advanced facilities and experienced medical professionals.
North America leads the global androgen deprivation therapy market with the high prevalence of prostate cancer, massive R&D investments, advanced healthcare expenditure and development novel immunotherapies. Europe holds the second largest global androgen deprivation therapy market with its advanced healthcare facilities and massive research investments.
Asia-Pacific androgen deprivation therapy market is the fastest emerging and is driven by the increasing burden of prostate cancer, increasing awareness, and government aids, improving healthcare facilities and advancing research.
Latin America androgen deprivation therapy market is growing with the increasing prevalence of prostate cancer, progressing research and healthcare facilities. The Middle East & Africa androgen deprivation therapy market is least lucrative due to the lack of awareness and underdeveloped healthcare infrastructure.
The key players of the global androgen deprivation therapy market include Allergan plc, Amgen, Bayer, AstraZeneca, Johnson & Johnson, Pfizer, Sanofi and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
To know more about delivery timeline for this report Contact Sales
